Manufactured by Novo Nordisk
First of its kind: Rybelsus was the first FDA-approved oral GLP-1 receptor agonist (September 2019). It is approved only for type 2 diabetes, not weight management. For the FDA-approved oral semaglutide for chronic weight management, see Wegovy Pill.
FDA-approved oral semaglutide for type 2 diabetes. 3mg, 7mg, or 14mg tablets taken once daily on an empty stomach, at least 30 minutes before the first food, beverage, or other oral medications of the day.
FDA Status
FDA Approved
Route
oral
Approved Indications
Typical Dose Range
3mg, 7mg, or 14mg daily
Dosing is determined by your prescribing provider based on your individual needs. Most GLP-1 medications follow a gradual titration schedule, starting at a low dose and increasing over several weeks to reduce side effects.
Branded (Retail)
$1,000/mo
Savings Program
N/A
Prices are estimates and may vary by pharmacy, location, and insurance coverage. Contact your provider for accurate pricing.
This is not a complete list of side effects. Talk to your healthcare provider about what to expect and when to seek medical attention.
This site is for educational purposes only and is not medical advice. Always consult a healthcare provider before starting any medication. Full disclaimer
